Cynata Therapeutics Receives R&D Tax Incentive Refund
Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company, announced it has received a $1,711,618 R&D Tax Incentive Refund for the 2024/2025 financial year.
The company focuses on developing therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology.
Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products.
The R&D Tax Incentive is an Australian Government program designed to encourage companies to invest in research and development activities within Australia.
Author's summary: Cynata Therapeutics receives $1.7 million refund.
More News
- Government to join forces with employers to tackle ill-health
- Claudia Sheinbaum harassment incident highlights violence against women in Mexico
- Bridget Phillipson must not abandon special needs children | The Spectator Australia
- The fascinating images of storms across the world
- From the white Iberian lynx in Spain to the howler monkeys of Costa Rica: Why do animals change color?
- Nassau police officer Ian Fogarty honored by county legislature
- Comment | Time is running out for justice on Nazi-looted art—but it is not yet too late for museums to act
- Employers must monitor workloads to protect staff wellbeing, says UNISON | Article, News, Press release | News | UNISON National
- Mayfield urges “fundamental shift” in approach to workplace health
- Roche Launches First AI-Enabled Continuous Glucose Monitor In South Africa - iAfrica.com